KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EPS (Weighted Average and Diluted) (2016 - 2025)

Medpace Holdings (MEDP) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with $4.63 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 26.16% year-over-year to $4.63, compared with a TTM value of $15.28 through Dec 2025, up 20.98%, and an annual FY2025 reading of $15.28, up 20.98% over the prior year.
  • EPS (Weighted Average and Diluted) was $4.63 for Q4 2025 at Medpace Holdings, up from $3.86 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $4.63 in Q4 2025 and bottomed at $1.06 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $2.45, with a median of $2.24 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 65.62% in 2021, while the deepest fall reached 1.49% in 2021.
  • Year by year, EPS (Weighted Average and Diluted) stood at $1.32 in 2021, then skyrocketed by 59.09% to $2.1 in 2022, then grew by 17.14% to $2.46 in 2023, then skyrocketed by 49.19% to $3.67 in 2024, then grew by 26.16% to $4.63 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for MEDP at $4.63 in Q4 2025, $3.86 in Q3 2025, and $3.12 in Q2 2025.